KAN-101 completed their Phase 1 clinical trial. The
drug was given to about 60 patients. Researchers
found that the immune response to gluten challenge
was greatly reduced, almost eliminated. Other parts of
the immune system were not affected. Phase 2
clinical trials are expected to start at the end of 2022.
While super exciting, this is only Phase 1 tested in a
small group and there is still a long, long way to go. It
is a great start, though!
https://www.businesswire.com/news/home/
20220523005182
/en/Anokion-Announces-Positive-Data-from-Phase-1
-ACeD-Clinical-Trial-Evaluating-KAN-101
-as-a-Treatment-for-Celiac-Disease-Presented-in-a-Ple
nary-Session-at-DDW-2022

TAK-101 completed their Phase 2a clinical trial
inducing an 88% reduction in villous atrophy during a
14 day gluten challenge compared to placebo. Phase
2 trials slated to start June 2022 and expected to end
in 2024. https://pubmed.ncbi.nlm.nih.gov/33722583/

Exocrine Pancreatic Insufficiency (EPI) affects just over
a quarter of newly diagnosed celiac patients.
https://mdpi-res.com/d_attachment/medicina/medicina
-56-00523/article_deploy/medicina-56-00523-v2
.pdf?version=1616053242

A lot of information summarized quickly for you today.
There are other drugs in the celiac pipeline, but these
are the ones with the most recent updates!
#glutensensitivity #glutenfreerecipes #glutenfree
#celiacdisease #celiac